Department of Hematology and Oncology, Beilun District People's Hospital, Ningbo, Zhejiang, China.
Liuzhou People's Hospital, Liuzhou, Guangxi, China.
Channels (Austin). 2021 Dec;15(1):680-696. doi: 10.1080/19336950.2021.2004758.
Pannexin 1 (PANX1) channel is a critical ATP-releasing pathway that modulates tumor immunity, progression, and prognosis. However, the roles of PANX1 in different cancers remain unclear. We analyzed the expression of PANX1 in human pan-cancer in the Oncomine and GEPIA2.0 databases. The prognostic value of PANX1 expression was determined using Kaplan-Meier plotter and OncoLnc tools. The correlation between PANX1 and tumor-infiltrating immune cells was investigated using the TIMER 2.0. In addition, the relationship between PANX1 and immunomodulators was explored using TISIDB. Finally, gene set enrichment analysis (GSEA) was performed utilizing LinkedOmics. The results indicated that PANX1 was overexpressed in most cancers compared to normal tissues. The high expression of PANX1 was associated with poor prognosis in multiple tumors, especially in pancreatic adenocarcinoma (PAAD). In addition, PANX1 was correlated with a variety of immunomodulators, such as CD274, IL10, CD276, IL2RA, TAP1, and TAP2. PANX1 expression level was significantly related to infiltration of multiple immune cells in many cancers, including cancer associated fibroblast, macrophage, and neutrophil cells. Further analysis revealed that PANX1 was significantly associated with T cells CD8+ (rho = 0.524, = 1.94e-13) and Myeloid dendritic cell (rho = 0.564, = 9.45e-16). GSEA results showed that PANX1 was closely associated with leukocyte cell-cell adhesion, endoplasmic reticulum lumen, ECM-receptor interaction, and Focal adhesion pathways in PAAD. PANX1 expression was higher in pan-cancer samples than in normal tissues. The high expression of PANX1 was associated with poor outcome and immune infiltration in multiple cancers, especially in PAAD.
连接蛋白 1（PANX1）通道是一种关键的 ATP 释放途径，可调节肿瘤免疫、进展和预后。然而，PANX1 在不同癌症中的作用尚不清楚。我们在 Oncomine 和 GEPIA2.0 数据库中分析了人类泛癌中 PANX1 的表达。使用 Kaplan-Meier plotter 和 OncoLnc 工具确定 PANX1 表达的预后价值。使用 TIMER 2.0 研究了 PANX1 与肿瘤浸润免疫细胞之间的相关性。此外，使用 TISIDB 探讨了 PANX1 与免疫调节剂之间的关系。最后，利用 LinkedOmics 进行基因集富集分析（GSEA）。结果表明，与正常组织相比，PANX1 在大多数癌症中表达上调。PANX1 的高表达与多种肿瘤的不良预后相关，尤其是胰腺导管腺癌（PAAD）。此外，PANX1 与多种免疫调节剂相关，如 CD274、IL10、CD276、IL2RA、TAP1 和 TAP2。PANX1 表达水平与许多癌症中多种免疫细胞的浸润显著相关，包括癌症相关成纤维细胞、巨噬细胞和中性粒细胞。进一步分析表明，PANX1 与 T 细胞 CD8+（rho = 0.524， = 1.94e-13）和髓样树突状细胞（rho = 0.564， = 9.45e-16）显著相关。GSEA 结果表明，PANX1 与 PAAD 中的白细胞细胞-细胞黏附、内质网腔、ECM-受体相互作用和焦点黏附途径密切相关。PANX1 在泛癌样本中的表达高于正常组织。PANX1 的高表达与多种癌症的不良结局和免疫浸润相关，尤其是在 PAAD 中。
